Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 2Unknown 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 317Squamous Cell Carcinoma of Head and Neck 168Head and Neck Neoplasms 150Carcinoma, Non-Small-Cell Lung 97Colonic Neoplasms 90Rectal Neoplasms 82Neoplasm Metastasis 72Neoplasms 60Pancreatic Neoplasms 40Carcinoma, Squamous Cell 40Lung Neoplasms 35Esophageal Neoplasms 25Breast Neoplasms 22Stomach Neoplasms 20Recurrence 20Carcinoma 18Laryngeal Neoplasms 17Tongue Neoplasms 16Mouth Neoplasms 16Oropharyngeal Neoplasms 14Esophageal Squamous Cell Carcinoma 14Salivary Gland Neoplasms 12Adenocarcinoma Of Esophagus 12Hypopharyngeal Neoplasms 11Colorectal Cancer Metastatic 11Laryngeal Diseases 10Adenocarcinoma of Lung 10Uterine Cervical Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 9Ovarian Neoplasms 9

Interventions

Oxaliplatin 4Cetuximab 4regorafenib 3Irinotecan 3Capecitabine 3trifluridine tipiracil drug combination 2surufatinib 2Fluorouracil 2Drug Therapy 2Bevacizumab 2raltitrexed 1plocabulin 1paclitaxel poliglumex 1nimotuzumab 1irinotecan sucrosofate 1endostar protein 1durvalumab 1defactinib 1aflibercept 1Panitumumab 1N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide 1HMPL-013 1Folfox protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Advanced Colorectal Cancer × Cetuximab × Clear all
NCT06369259 2026-05-20

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Advanced Colorectal Cancer

NCT02826837 2021-10-06

LEAC-102 for Advanced Colorectal Cancer

Taiwan Leader Biotech Corp.

Phase 1/2 Unknown
30 enrolled
Gastrointestinal

Advanced Colorectal Cancer

NCT00637091 2021-01-22

Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions

Asan Medical Center

Phase 2 Completed
40 enrolled
Gastrointestinal

Advanced Colorectal Cancer

NCT00309179 2017-09-14

A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors

Eisai Inc.

Phase 2 Completed
41 enrolled
Gastrointestinal

Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡